Medications for Cystic Fibrosis

8 results

  • acetylcysteine

    (Acetylcysteine)
    Somerset Therapeutics, LLC
    Acetylcysteine solution, USP is indicated as adjuvant therapy for abnormal mucous secretions in chronic and acute bronchopulmonary diseases, pulmonary complications of cystic fibrosis, tracheostomy care, surgical pulmonary complications, anesthetic use, post-traumatic chest conditions, atelectasis due to mucous obstruction, and diagnostic bronchial studies.

  • alyftrek

    (vanzacaftor, tezacaftor, and deutivacaftor)
    Vertex Pharmaceuticals Incorporated
    ALYFTREK is indicated for treating cystic fibrosis in patients aged 6 and older with at least one F508del mutation or another responsive CFTR mutation. An FDA-cleared CF mutation test is recommended if the patient's genotype is unknown.

  • kalydeco

    (ivacaftor)
    Vertex Pharmaceuticals Incorporated
    KALYDECO is indicated for treating cystic fibrosis in patients aged 1 month and older with at least one responsive CFTR gene mutation. A CF mutation test is recommended if the patient's genotype is unknown to confirm a CFTR mutation.

  • orkambi

    (lumacaftor and ivacaftor)
    Vertex Pharmaceuticals Incorporated
    ORKAMBI is indicated for the treatment of cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Efficacy and safety have not been established in other CF genotypes. Testing for the mutation is recommended if unknown.

  • south moon toothache

    (GLYCERIN)
    Shantou South Moon Biotechnology Co., Ltd.
    It appears there is no specific information provided in your message regarding the drug in question. Please provide the details or text from the drug label so I can assist you in summarizing its indications and usages.

  • symdeko

    (Tezacaftor and Ivacaftor)
    Vertex Pharmaceuticals Incorporated
    SYMDEKO is indicated for treating cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or have a responsive CFTR mutation, as determined by in vitro data or clinical evidence. Testing is recommended for patients with an unknown genotype.

  • tobramycin inhalation

    (tobramycin inhalation)
    Prasco, LLC
    Tobramycin Inhalation Solution is indicated for managing cystic fibrosis in patients with Pseudomonas aeruginosa. Its safety and efficacy are not established in individuals under six years, those with FEV1 less than 40% or greater than 80%, or patients colonized with Burkholderia cepacia.

  • trikafta

    (Elexacaftor, Tezacaftor, and Ivacaftor)
    Vertex Pharmaceuticals Incorporated
    TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation in the CFTR gene, or other responsive CFTR mutations verified by clinical or laboratory data. An FDA-cleared CF mutation test is recommended if the genotype is unknown.